Skip to main content
FDA grants Fast Track status to fosmanogepix's oral, IV formulations

Fast Track designations were granted by the FDA for the oral and intravenous formulations of Amplyx Pharmaceuticals' fosmanogepix, or APX001. The antifungal can be used as a treatment for seven indications, which include coccidioidomycosis, cryptococcosis, fusariosis, invasive aspergillosis, invasive candidiasis, mucormycosis, and scedosporiosis.

Full Story: